CVE:RVV

Revive Therapeutics Competitors

C$0.08
+0.01 (+14.29 %)
(As of 07/22/2019)
Add
Compare
Today's Range
C$0.08
Now: C$0.08
C$0.09
50-Day Range
C$0.08
MA: C$0.08
C$0.08
52-Week Range
C$0.07
Now: C$0.08
C$0.25
Volume212,852 shs
Average Volume93,085 shs
Market CapitalizationC$5.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Revive Therapeutics (CVE:RVV) Vs. KNE, GSD, PAS, NSP, MPH, and BTI

Should you be buying RVV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Revive Therapeutics, including Kane Biotech (KNE), Devonian Health Group (GSD), Pascal Biosciences (PAS), Naturally Splendid Enterprises (NSP), Medicure (MPH), and Bioasis Technologies (BTI).

Kane Biotech (CVE:KNE) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Kane Biotech and Revive Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kane BiotechN/AN/AN/A
Revive TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Kane Biotech and Revive Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kane Biotech0000N/A
Revive Therapeutics0000N/A

Earnings and Valuation

This table compares Kane Biotech and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kane BiotechC$1.34 million13.36C$-3,801,490.00C($0.04)-4.71
Revive TherapeuticsN/AN/AN/AC($0.02)-3.64

Revive Therapeutics has lower revenue, but higher earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Revive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Revive Therapeutics beats Kane Biotech on 2 of the 3 factors compared between the two stocks.

Devonian Health Group (CVE:GSD) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Devonian Health Group and Revive Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Devonian Health GroupN/AN/AN/A
Revive TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Devonian Health Group and Revive Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Devonian Health Group0000N/A
Revive Therapeutics0000N/A

Earnings and Valuation

This table compares Devonian Health Group and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Devonian Health GroupC$1.59 million15.20C$-4,457,184.00C($0.05)-5.42
Revive TherapeuticsN/AN/AN/AC($0.02)-3.64

Revive Therapeutics has lower revenue, but higher earnings than Devonian Health Group. Devonian Health Group is trading at a lower price-to-earnings ratio than Revive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Revive Therapeutics beats Devonian Health Group on 2 of the 3 factors compared between the two stocks.

Pascal Biosciences (CVE:PAS) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Pascal Biosciences and Revive Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
Revive TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Pascal Biosciences and Revive Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
Revive Therapeutics0000N/A

Earnings and Valuation

This table compares Pascal Biosciences and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-3.86
Revive TherapeuticsN/AN/AN/AC($0.02)-3.64

Pascal Biosciences is trading at a lower price-to-earnings ratio than Revive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Revive Therapeutics beats Pascal Biosciences on 1 of the 1 factors compared between the two stocks.

Naturally Splendid Enterprises (CVE:NSP) and Revive Therapeutics (CVE:RVV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Naturally Splendid Enterprises and Revive Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Naturally Splendid EnterprisesN/AN/AN/A
Revive TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Naturally Splendid Enterprises and Revive Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Naturally Splendid EnterprisesC$2.03 million6.99C$-9,371,678.00C($0.04)-1.51
Revive TherapeuticsN/AN/AN/AC($0.02)-3.64

Revive Therapeutics has lower revenue, but higher earnings than Naturally Splendid Enterprises. Revive Therapeutics is trading at a lower price-to-earnings ratio than Naturally Splendid Enterprises, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Naturally Splendid Enterprises and Revive Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Naturally Splendid Enterprises0000N/A
Revive Therapeutics0000N/A

Summary

Naturally Splendid Enterprises beats Revive Therapeutics on 2 of the 3 factors compared between the two stocks.

Revive Therapeutics (CVE:RVV) and Medicure (CVE:MPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Revive Therapeutics and Medicure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revive TherapeuticsN/AN/AN/A
MedicureN/AN/AN/A

Valuation & Earnings

This table compares Revive Therapeutics and Medicure's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revive TherapeuticsN/AN/AN/AC($0.02)-3.64
MedicureC$12.71 million1.32C$-16,189,063.70C($1.55)-1.04

Revive Therapeutics has higher earnings, but lower revenue than Medicure. Revive Therapeutics is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Revive Therapeutics and Medicure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revive Therapeutics0000N/A
Medicure0000N/A

Summary

Medicure beats Revive Therapeutics on 2 of the 3 factors compared between the two stocks.

Revive Therapeutics (CVE:RVV) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Revive Therapeutics and Bioasis Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revive TherapeuticsN/AN/AN/A
Bioasis TechnologiesN/AN/AN/A

Valuation & Earnings

This table compares Revive Therapeutics and Bioasis Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revive TherapeuticsN/AN/AN/AC($0.02)-3.64
Bioasis TechnologiesC$4.12 million5.94C$790,284.00C$0.0130.91

Bioasis Technologies has higher revenue and earnings than Revive Therapeutics. Revive Therapeutics is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Revive Therapeutics and Bioasis Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revive Therapeutics0000N/A
Bioasis Technologies0000N/A

Summary

Bioasis Technologies beats Revive Therapeutics on 3 of the 3 factors compared between the two stocks.


Revive Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
KNE
Kane Biotech
0.4$0.17+3.0%C$14.12 millionC$1.34 million-4.71Gap Down
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.09+11.8%C$12.70 millionN/A-3.86High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.07+7.7%C$11.06 millionC$2.03 million-1.51
MPH
Medicure
0.7$1.61+1.9%C$10.80 millionC$12.71 million-1.04
BTI
Bioasis Technologies
0.7$0.34+13.2%C$10.16 millionC$4.12 million30.91High Trading Volume
Gap Up
HEM
Hemostemix
0.6$0.37+1.4%C$9.07 millionN/A-2.20
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.40+7.6%C$6.94 millionC$5.60 million7.31Gap Down
IOT
Innovotech
0.8$0.16+6.3%C$6.52 millionC$1.04 million80.00
BCT
BriaCell Therapeutics
0.5$4.10+2.4%C$4.48 millionN/A-1.32
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.18+0.0%C$0.00C$267.59 million50.75News Coverage
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.